Caredx Stock Price, News & Analysis

CareDx, Inc. (Nasdaq: CDNA) announced its participation at the 36th European Immunogenetics and Histocompatibility Conference from April 26-29 in Nantes, France. The company will showcase its AlloSeq portfolio for HLA typing and organ transplant monitoring, highlighting innovations in precision medicine for transplant patients.

The event will feature a symposium focused on innovative pre- and post-transplant solutions, moderated by Curtis Lind, with discussions led by various experts on HLA typing and chimerism analysis. CareDx emphasizes its commitment to advancing immunogenetics and supporting the European transplant community.

The AlloSeq products aim to enhance pre- and post-transplant care, reinforcing CareDx’s leadership in the transplant genomics market.

CareDx, Inc. (CDNA) announces its significant participation in the 43rd annual meeting of the International Society for Heart and Lung Transplantation (ISHLT) in Denver, Colorado, showcasing over 55 presentations on advancements in heart and lung transplantation. The presentation highlights the clinical benefits of HeartCare and AlloSure Lung, focusing on their utility in post-transplant care. Experts, including Dr. Jeffrey Teuteberg from Stanford, advocate for moving away from biopsies to molecular surveillance for better outcomes. The event takes place from April 19-22, underscoring CareDx's commitment to enhancing clinical decision-making with its non-invasive solutions. CEO Reg Seeto emphasizes that the research will provide insights into patient care.

CareDx, a leader in precision medicine for transplant patients, has announced its sponsorship of the 12th Congress of the International Pediatric Transplant Association (IPTA) from March 25-28, 2023, in Austin, Texas. The company will host a symposium titled "Paradigm Shifts in Pediatric Surveillance Testing: AlloSure and AlloMap in Action" on March 26, featuring expert speakers from notable institutions. CEO Reg Seeto emphasized CareDx's commitment to pediatric transplant innovation, highlighting advancements in non-invasive monitoring with their products, AlloSure and AlloMap. This event aims to enhance awareness and usage of these monitoring solutions among pediatric transplant professionals.

CareDx, Inc. (Nasdaq: CDNA) announced the American Society of Transplant Surgeons (ASTS) supports its AlloSure Kidney and AlloMap Heart testing for organ transplant surveillance. The ASTS position statement endorses the use of donor-derived cell-free DNA (dd-cfDNA) to monitor kidney transplant recipients, particularly to rule out subclinical antibody-mediated rejection (ABMR). It also recommends dd-cfDNA for heart transplants and peripheral blood gene expression profiling as a non-invasive diagnostic tool for heart transplant recipients over 55 days post-transplant. CEO Reg Seeto praised ASTS for this leadership.

CareDx, Inc. (NASDAQ: CDNA) announced it will not participate in the Raymond James & Associates' 44th Annual Institutional Investors Conference due to scheduling conflicts. The Company is focused on providing high-value healthcare solutions for transplant patients and their caregivers. CareDx specializes in precision medicine, offering testing services and digital healthcare solutions throughout the transplant journey. The Company looks forward to releasing its next corporate update soon, indicating ongoing engagement with investors and stakeholders.

CareDx, Inc. (NASDAQ: CDNA), known as The Transplant Company™, announced its participation in the Raymond James & Associates’ 44th Annual Institutional Investors Conference. The presentation is scheduled for Monday, March 6, 2023, at 4:35 PM ET. Investors can access the webcast by visiting CareDx's investor relations page at investors.caredxinc.com. CareDx is a leader in precision medicine solutions, offering innovative testing services and digital healthcare solutions for transplant patients throughout their journey.

CareDx, Inc. (NASDAQ: CDNA) announced the release of a Billing Article regarding MolDX Molecular Testing for Solid Organ Allograft Rejection, effective March 31, 2023. CEO Reg Seeto clarified that MolDX will not modify the foundational LCD but issued this article for clarification. Key points include reimbursement coverage for testing services, standalone billing for AlloSure Heart, which can now be billed separately from AlloMap Heart, and a pathway for multimodality testing with additional data. CareDx plans to engage further with MolDX and update their HeartCare submission and procedures accordingly.